TLR5 Receptor Identified as Key Protective Pathway in Idiopathic Pulmonary Fibrosis, Mouse Studies Show Therapeutic Promise
核心洞察
A Greek-led international team identified the immune receptor TLR5 (搜索) as a novel therapeutic target for idiopathic pulmonary fibrosis (搜索) (IPF), a life-threatening lung disease with no cure.
Genetic analysis of over 1,100 IPF patients and 2,500 healthy individuals revealed a clear association between reduced TLR5 (搜索) function and disease susceptibility.
Mice lacking functional TLR5 (搜索) receptors were significantly more susceptible to pulmonary fibrosis, while activating TLR5 with a bacterial protein protected animals from developing the condition.
A research team led by Greek pulmonologist Dr. Stavros Garantziotis has uncovered a previously unknown mechanism driving idiopathic pulmonary fibrosis (搜索) (IPF), identifying the immune receptor TLR5 (搜索) as both a key protective factor and a promising therapeutic target. The findings, published in Science Translational Medicine, represent the first genetic link established between the lung microbiome and this devastating disease.
IPF is a life-threatening condition in which lung tissue becomes progressively scarred, making breathing increasingly difficult and eventually leading to respiratory failure and death for many patients. Two currently approved drugs can slow disease progression but have not been shown to improve symptoms, and the biological mechanisms triggering the disease have remained largely unknown.
"We found that TLR5 (搜索) receptors in airway cells are activated in response to lung injury and stop the overgrowth of harmful types of bacterium," said Garantziotis, a clinician-researcher at the National Institute of Environmental Health Sciences (NIEHS) in Durham, North Carolina. IPF develops following injuries to the lung caused by smoking, repeat infections, and environmental exposures.
A Genetic Connection to the Lung Microbiome
The research team analyzed genetic data from more than 1,100 patients with idiopathic pulmonary fibrosis (搜索) and approximately 2,500 healthy individuals, finding a clear association between IPF and reduced TLR5 (搜索) function. The gene encodes a receptor that recognizes bacteria and triggers an immune response to infection. With a mutated gene, the receptors do not work properly, making the body more susceptible to infections.
The team then confirmed the finding in laboratory mice. Animals lacking a functional TLR5 (搜索) receptor proved significantly more susceptible to developing pulmonary fibrosis. In a critical proof-of-concept experiment, activating TLR5 using a specific bacterial protein stimulated the receptor's protective function, effectively shielding animal models from developing lung fibrosis.
Brian Oliver, a respiration and pollution researcher at the University of Technology Sydney in Australia, noted that the findings are exciting because they reveal a new pathway connected to IPF development. "It's a very novel idea to look at the TLR5 (搜索) receptor," he said, "because it is not something many people would associate with a fibrotic lung disease."
Beyond IPF: Implications for COPD
A second study by the same research group, currently awaiting publication, suggests TLR5 (搜索) may also protect against chronic obstructive pulmonary disease (搜索) (COPD). The researchers examined COPD patients, human cells, and animal models, finding that higher TLR5 activity in the lungs corresponded with lower levels of inflammatory markers in patients' blood. They also discovered that cigarette smoke suppresses TLR5 expression in airway cells.
"The activation of TLR5 (搜索) may improve lung function," Garantziotis said, adding that restoring the receptor's activity could become a new therapeutic strategy for chronic lung diseases.
Toward Clinical Translation
Not everyone who experiences lung injuries goes on to develop IPF, and a person's genetics along with the types of bacteria causing infections could play a determining role. Garantziotis emphasized that targeting the TLR5 (搜索) protein with drugs could prevent the disease from progressing.
The research team will now investigate which antibiotics may best restore healthy lung bacteria and whether medicines that directly activate TLR5 (搜索) can prevent or treat pulmonary fibrosis. "If we understand what causes the disease in each individual, we can develop treatments that target the root of the problem with much greater precision," Garantziotis said.